- Home
- INKT vs DXR Comparison
INKT vs DXR Comparison
Compare INKT & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- DXR
- Stock Information
- Founded
- INKT 2017
- DXR 1970
- Country
- INKT United States
- DXR United States
- Employees
- INKT N/A
- DXR N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- DXR Medical/Dental Instruments
- Sector
- INKT Health Care
- DXR Health Care
- Exchange
- INKT Nasdaq
- DXR Nasdaq
- Market Cap
- INKT 31.2M
- DXR 36.4M
- IPO Year
- INKT 2021
- DXR N/A
- Fundamental
- Price
- INKT $7.03
- DXR $7.75
- Analyst Decision
- INKT Strong Buy
- DXR Strong Buy
- Analyst Count
- INKT 2
- DXR 1
- Target Price
- INKT $37.50
- DXR $25.00
- AVG Volume (30 Days)
- INKT 2.8K
- DXR 4.8K
- Earning Date
- INKT 05-15-2025
- DXR 01-01-0001
- Dividend Yield
- INKT N/A
- DXR N/A
- EPS Growth
- INKT N/A
- DXR 86.16
- EPS
- INKT N/A
- DXR 0.11
- Revenue
- INKT N/A
- DXR $119,714.00
- Revenue This Year
- INKT N/A
- DXR N/A
- Revenue Next Year
- INKT N/A
- DXR N/A
- P/E Ratio
- INKT N/A
- DXR $70.84
- Revenue Growth
- INKT N/A
- DXR N/A
- 52 Week Low
- INKT $4.56
- DXR $6.55
- 52 Week High
- INKT $13.79
- DXR $10.00
- Technical
- Relative Strength Index (RSI)
- INKT 39.71
- DXR 51.69
- Support Level
- INKT $7.20
- DXR $7.13
- Resistance Level
- INKT $7.40
- DXR $7.74
- Average True Range (ATR)
- INKT 0.39
- DXR 0.33
- MACD
- INKT -0.02
- DXR 0.02
- Stochastic Oscillator
- INKT 27.41
- DXR 89.04
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.